Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?

Many cancer biomarker research studies seek to develop markers that can accurately detect or predict future onset of disease. To design and evaluate these studies, one must specify the levels of accuracy sought. However, justified target levels are rarely available. We describe a way to calculate ta...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical chemistry (Baltimore, Md.) Ročník 62; číslo 5; s. 737 - 742
Hlavní autori: Pepe, Margaret S, Janes, Holly, Li, Christopher I, Bossuyt, Patrick M, Feng, Ziding, Hilden, Jørgen
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Oxford University Press 01.05.2016
Predmet:
ISSN:0009-9147, 1530-8561
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Many cancer biomarker research studies seek to develop markers that can accurately detect or predict future onset of disease. To design and evaluate these studies, one must specify the levels of accuracy sought. However, justified target levels are rarely available. We describe a way to calculate target levels of sensitivity and specificity for a biomarker intended to be applied in a defined clinical context. The calculation requires knowledge of the prevalence or incidence of cases in the clinical population and the ratio of benefit associated with the clinical consequences of a positive biomarker test in cases (true positive) to cost associated with a positive biomarker test in controls (false positive). Guidance is offered on soliciting the cost/benefit ratio. The calculations are based on the longstanding decision theory concept of providing a net benefit on average in the population, and they rely on some assumptions about uniformity of costs and benefits to those tested. Calculations are illustrated with 3 applications: predicting colon cancer recurrence in stage 1 patients; predicting interval breast cancer (between mammography screenings); and screening for ovarian cancer. It is feasible to specify target levels of biomarker performance that enable evaluation of the potential clinical impact of biomarkers in early-phase studies. Nevertheless, biomarkers meeting the criteria should still be tested rigorously in studies that measure the actual impact on patient outcomes of using the biomarker to make clinical decisions.
AbstractList Many cancer biomarker research studies seek to develop markers that can accurately detect or predict future onset of disease. To design and evaluate these studies, one must specify the levels of accuracy sought. However, justified target levels are rarely available. We describe a way to calculate target levels of sensitivity and specificity for a biomarker intended to be applied in a defined clinical context. The calculation requires knowledge of the prevalence or incidence of cases in the clinical population and the ratio of benefit associated with the clinical consequences of a positive biomarker test in cases (true positive) to cost associated with a positive biomarker test in controls (false positive). Guidance is offered on soliciting the cost/benefit ratio. The calculations are based on the longstanding decision theory concept of providing a net benefit on average in the population, and they rely on some assumptions about uniformity of costs and benefits to those tested. Calculations are illustrated with 3 applications: predicting colon cancer recurrence in stage 1 patients; predicting interval breast cancer (between mammography screenings); and screening for ovarian cancer. It is feasible to specify target levels of biomarker performance that enable evaluation of the potential clinical impact of biomarkers in early-phase studies. Nevertheless, biomarkers meeting the criteria should still be tested rigorously in studies that measure the actual impact on patient outcomes of using the biomarker to make clinical decisions.
BACKGROUNDMany cancer biomarker research studies seek to develop markers that can accurately detect or predict future onset of disease. To design and evaluate these studies, one must specify the levels of accuracy sought. However, justified target levels are rarely available.METHODSWe describe a way to calculate target levels of sensitivity and specificity for a biomarker intended to be applied in a defined clinical context. The calculation requires knowledge of the prevalence or incidence of cases in the clinical population and the ratio of benefit associated with the clinical consequences of a positive biomarker test in cases (true positive) to cost associated with a positive biomarker test in controls (false positive). Guidance is offered on soliciting the cost/benefit ratio. The calculations are based on the longstanding decision theory concept of providing a net benefit on average in the population, and they rely on some assumptions about uniformity of costs and benefits to those tested.RESULTSCalculations are illustrated with 3 applications: predicting colon cancer recurrence in stage 1 patients; predicting interval breast cancer (between mammography screenings); and screening for ovarian cancer.CONCLUSIONSIt is feasible to specify target levels of biomarker performance that enable evaluation of the potential clinical impact of biomarkers in early-phase studies. Nevertheless, biomarkers meeting the criteria should still be tested rigorously in studies that measure the actual impact on patient outcomes of using the biomarker to make clinical decisions.
Many cancer biomarker research studies seek to develop markers that can accurately detect or predict future onset of disease. To design and evaluate these studies, one must specify the levels of accuracy sought. However, justified target levels are rarely available. We describe a way to calculate target levels of sensitivity and specificity for a biomarker intended to be applied in a defined clinical context. The calculation requires knowledge of the prevalence or incidence of cases in the clinical population and the ratio of benefit associated with the clinical consequences of a positive biomarker test in cases (true positive) to cost associated with a positive biomarker test in controls (false positive). Guidance is offered on soliciting the cost/benefit ratio. The calculations are based on the longstanding decision theory concept of providing a net benefit on average in the population, and they rely on some assumptions about uniformity of costs and benefits to those tested. Calculations are illustrated with 3 applications: predicting colon cancer recurrence in stage 1 patients; predicting interval breast cancer (between mammography screenings); and screening for ovarian cancer. It is feasible to specify target levels of biomarker performance that enable evaluation of the potential clinical impact of biomarkers in early-phase studies. Nevertheless, biomarkers meeting the criteria should still be tested rigorously in studies that measure the actual impact on patient outcomes of using the biomarker to make clinical decisions.
Author Bossuyt, Patrick M
Feng, Ziding
Pepe, Margaret S
Janes, Holly
Hilden, Jørgen
Li, Christopher I
AuthorAffiliation 4 Clinical Epidemiology, University of Amsterdam, Amsterdam, Netherlands
2 Vaccine and Infectious Disease Division, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
6 University of Copenhagen, Institute of Medical Genetics, Dept. of Biostatistics, Copenhagen, Denmark
3 Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
1 Biostatistics and Biomathematics Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
5 Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas
AuthorAffiliation_xml – name: 3 Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
– name: 2 Vaccine and Infectious Disease Division, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
– name: 1 Biostatistics and Biomathematics Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
– name: 5 Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas
– name: 4 Clinical Epidemiology, University of Amsterdam, Amsterdam, Netherlands
– name: 6 University of Copenhagen, Institute of Medical Genetics, Dept. of Biostatistics, Copenhagen, Denmark
Author_xml – sequence: 1
  givenname: Margaret S
  surname: Pepe
  fullname: Pepe, Margaret S
  organization: Biostatistics and Biomathematics Program, Public Health Sciences Division
– sequence: 2
  givenname: Holly
  surname: Janes
  fullname: Janes, Holly
  organization: Vaccine and Infectious Disease Division, Public Health Sciences Division, and
– sequence: 3
  givenname: Christopher I
  surname: Li
  fullname: Li, Christopher I
  organization: Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
– sequence: 4
  givenname: Patrick M
  surname: Bossuyt
  fullname: Bossuyt, Patrick M
  organization: Clinical Epidemiology, University of Amsterdam, Amsterdam, Netherlands
– sequence: 5
  givenname: Ziding
  surname: Feng
  fullname: Feng, Ziding
  organization: Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX
– sequence: 6
  givenname: Jørgen
  surname: Hilden
  fullname: Hilden, Jørgen
  organization: Department of Biostatistics, Institute of Medical Genetics, University of Copenhagen, Copenhagen, Denmark
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27001493$$D View this record in MEDLINE/PubMed
BookMark eNp9kdFqFDEUhoNU7Hb1DUQC3ngzazKZzMz2wqJLq0JFYVu9DGcyyU5qNlmTTGHfvhm2LdoLr8Ih3384P98JOnLeKYReU7KgrGHvpTVODmq7KAnli5KXtGbP0IxyRoqW1_QIzQghy2JJq-YYncR4k8eqaesX6LhsCKHVks3Q7hyC3Rc_BogKr9PYGxWx1_iT8VsIv1WIp_jXAAlfQdiohNfKRZPMrUl7DK7H652SRhs5zT_Bjjn9zWyGhFfeaRXwKl9pJFh8nYzN0NlL9FyDjerV_TtH1xfnV6svxeX3z19XHy8LyUmZCsa6GqBpuO6kbpccGqZakGVJle56gK4l7VLpnlGtK-hqlrEeSNt1nZKlqtkcfTjs3Y3dVvVSuRTAil0wuddeeDDi3x9nBrHxt4ITwiiZFry7XxD8n9wria2JUlkLTvkxCtq0vKlomV3M0dsn6I0fg8v1JqrmLeWkytSbvy96POVBRgaqAyCDjzEo_YhQIibn4sG5mJyLg_McO30SyzYgGT_1Mvb_4Ts3YLfR
CitedBy_id crossref_primary_10_1002_ijc_31900
crossref_primary_10_1016_S2213_2600_18_30528_9
crossref_primary_10_1016_j_clinms_2020_08_001
crossref_primary_10_1177_0004563219842265
crossref_primary_10_1186_s13148_023_01440_w
crossref_primary_10_1016_j_jclinepi_2020_01_028
crossref_primary_10_1111_biom_13911
crossref_primary_10_4155_bio_2020_0198
crossref_primary_10_1016_j_pan_2025_04_017
crossref_primary_10_1038_s41571_018_0036_9
crossref_primary_10_3390_mi11030291
crossref_primary_10_1016_j_pharmthera_2021_107806
crossref_primary_10_1186_s12931_023_02327_3
crossref_primary_10_1038_s41380_019_0636_5
crossref_primary_10_1164_rccm_201708_1678ST
crossref_primary_10_1002_sim_8890
crossref_primary_10_1016_j_trsl_2023_07_011
crossref_primary_10_1007_s12035_017_0609_0
crossref_primary_10_1016_j_jclinepi_2019_09_017
crossref_primary_10_1186_s41512_019_0069_2
crossref_primary_10_1016_j_jss_2019_08_004
crossref_primary_10_1016_j_ijmedinf_2024_105523
crossref_primary_10_1080_03610926_2021_2001016
crossref_primary_10_1093_biomtc_ujaf067
crossref_primary_10_3390_cancers12092428
crossref_primary_10_1111_biom_13190
crossref_primary_10_1177_1177271917751608
crossref_primary_10_1016_j_jclinepi_2023_06_001
crossref_primary_10_1080_10543406_2016_1226335
crossref_primary_10_1007_s43032_022_00863_9
crossref_primary_10_1016_j_jclinepi_2019_05_002
crossref_primary_10_1186_s12916_025_04035_9
crossref_primary_10_1136_bmjopen_2018_027287
crossref_primary_10_1093_jalm_jfae054
crossref_primary_10_1016_j_ecolind_2019_03_054
crossref_primary_10_1080_24709360_2021_1878406
crossref_primary_10_3390_cancers15041256
crossref_primary_10_1053_j_gastro_2018_05_023
crossref_primary_10_1158_1940_6207_CAPR_23_0317
crossref_primary_10_3390_jcm9061790
crossref_primary_10_1016_j_ccm_2019_10_004
crossref_primary_10_1007_s43441_022_00495_w
crossref_primary_10_1016_j_jtha_2023_01_003
crossref_primary_10_3390_cancers14143306
crossref_primary_10_3390_math10224206
crossref_primary_10_1158_1055_9965_EPI_23_1594
crossref_primary_10_1016_j_nicl_2021_102898
crossref_primary_10_1007_s00404_017_4587_2
crossref_primary_10_1186_s12885_020_07468_y
crossref_primary_10_1371_journal_pone_0218942
crossref_primary_10_1176_appi_ajp_2020_20030340
crossref_primary_10_1186_s12957_025_03957_1
crossref_primary_10_1016_j_ophtha_2021_08_023
crossref_primary_10_1016_j_pan_2024_10_012
crossref_primary_10_1016_j_annepidem_2018_07_014
crossref_primary_10_1111_sltb_70041
crossref_primary_10_1373_clinchem_2016_254268
crossref_primary_10_1007_s10620_024_08800_3
crossref_primary_10_1007_s12561_022_09343_9
Cites_doi 10.1093/oso/9780198509844.001.0001
10.1093/jnci/djn326
10.1038/bjc.2011.3
10.1373/clinchem.2012.185140
10.1001/jama.2015.37
10.1056/NEJM197507312930505
10.1016/S1470-2045(09)70026-9
10.1093/jnci/djn215
10.1093/jnci/dju355
10.1021/pr400132j
10.1158/1055-9965.EPI-14-1227
10.1093/jnci/93.14.1054
10.7326/0003-4819-122-5-199503010-00001
10.1177/0272989X06295361
10.1258/jms.2008.007016
10.7326/M13-2841
ContentType Journal Article
Copyright 2016 American Association for Clinical Chemistry.
Copyright American Association for Clinical Chemistry May 2016
Copyright_xml – notice: 2016 American Association for Clinical Chemistry.
– notice: Copyright American Association for Clinical Chemistry May 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
4U-
7QO
7RV
7TM
7U7
7X7
7XB
88E
88I
8AO
8C1
8FD
8FE
8FG
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
BGLVJ
BHPHI
BKSAR
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB.
KB0
M0S
M1P
M2P
NAPCQ
P64
PCBAR
PDBOC
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
RC3
S0X
7X8
5PM
DOI 10.1373/clinchem.2015.252163
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
University Readers
Biotechnology Research Abstracts
Nursing & Allied Health Database
Nucleic Acids Abstracts
Toxicology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Technology Collection
Natural Science Collection
Earth, Atmospheric & Aquatic Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Science Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
Earth, Atmospheric & Aquatic Science Database
Materials Science Collection
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central Basic
Genetics Abstracts
SIRS Editorial
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest One Academic Eastern Edition
Earth, Atmospheric & Aquatic Science Database
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
University Readers
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
SIRS Editorial
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central
Earth, Atmospheric & Aquatic Science Collection
ProQuest Health & Medical Research Collection
Genetics Abstracts
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Central Basic
Toxicology Abstracts
ProQuest Science Journals
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
ProQuest Medical Library
Materials Science & Engineering Collection
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1530-8561
EndPage 742
ExternalDocumentID PMC5003106
4043934871
27001493
10_1373_clinchem_2015_252163
Genre Journal Article
Research Support, N.I.H., Extramural
Feature
GrantInformation_xml – fundername: NIGMS NIH HHS
  grantid: R01 GM054438
– fundername: NCI NIH HHS
  grantid: R01 CA152089
– fundername: NCI NIH HHS
  grantid: U24 CA086368
– fundername: NCI NIH HHS
  grantid: P30 CA016672
GroupedDBID ---
-~X
.55
04C
0R~
18M
29B
2WC
4.4
53G
5GY
5RE
5VS
5WD
6J9
7RV
7X7
88E
88I
8AO
8C1
8FE
8FG
8FH
8FI
8FJ
8R4
8R5
AABZA
AACZT
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAVAP
AAYXX
ABCQX
ABDFA
ABEJV
ABGNP
ABJCF
ABJNI
ABMNT
ABNHQ
ABOCM
ABPPZ
ABPQP
ABPTD
ABQNK
ABSQV
ABUWG
ABVGC
ABWST
ABXVV
ABXZS
ACGOD
ACIHN
ACIWK
ACPRK
ACUTJ
ACYHN
ADBBV
ADGKP
ADGZP
ADIPN
ADNBA
ADQBN
ADVEK
AEAQA
AELWJ
AEMQT
AENEX
AETBJ
AEUYN
AFFHD
AFFZL
AFGWE
AFKRA
AFRAH
AFXAL
AFYAG
AGINJ
AGQXC
AGUTN
AHMBA
AHMMS
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALXQX
ATGXG
AZQEC
BAIFH
BAWUL
BBTPI
BCRHZ
BENPR
BEYMZ
BGLVJ
BHPHI
BKEYQ
BKSAR
BMSDO
BPHCQ
BTFSW
BVXVI
C45
CCPQU
CITATION
CS3
D1I
DU5
DWQXO
E3Z
EBD
EBS
EIHBH
EJD
EMOBN
ENERS
EX3
F5P
F9R
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
FYUFA
GAUVT
GNUQQ
H13
HCIFZ
HMCUK
H~9
IH2
INIJC
INR
JXSIZ
KB.
KBUDW
KOP
KQ8
KSI
KSN
L7B
LK5
M1P
M2P
M7R
ML-
NAPCQ
NOMLY
NU-
OAUYM
OBOKY
OCZFY
OJZSN
OPAEJ
OVD
OWPYF
PCBAR
PDBOC
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PV9
Q2X
R0Z
RHI
RNS
ROX
RUSNO
RZL
S0X
SV3
TCC
TEORI
TR2
TWZ
U5U
UKHRP
UNMZH
W8F
WH7
WOQ
WOW
X7M
YBU
YHG
YSK
YWH
YXANX
ZCG
.GJ
1KJ
AAPGJ
AAWDT
ABEFU
ACFRR
ACVCV
ACZBC
ADMTO
AFFNX
AFFQV
AGKRT
AGMDO
AI.
AJDVS
ALIPV
APJGH
AQDSO
AVNTJ
BES
C1A
CGR
CUY
CVF
ECM
EIF
EIHJH
J5H
MVM
NPM
OBFPC
TMA
VH1
YQJ
ZE2
ZGI
~V8
3V.
4U-
7QO
7TM
7U7
7XB
8FD
8FK
ARBBW
C1K
FR3
K9.
P64
PKEHL
PQEST
PQUKI
Q9U
RC3
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c502t-33b6aa775fbcf895a73e8ac221efbdaab8089efd31ff4ab63bcfda08bbbec2e63
IEDL.DBID BENPR
ISICitedReferencesCount 64
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000375173400016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0009-9147
IngestDate Tue Nov 04 01:53:39 EST 2025
Sun Sep 28 00:03:16 EDT 2025
Tue Oct 07 05:28:09 EDT 2025
Thu Apr 03 07:26:12 EDT 2025
Sat Nov 29 07:49:26 EST 2025
Tue Nov 18 22:13:25 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
2016 American Association for Clinical Chemistry.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c502t-33b6aa775fbcf895a73e8ac221efbdaab8089efd31ff4ab63bcfda08bbbec2e63
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/clinchem/article-pdf/62/5/737/32644203/clinchem0737.pdf
PMID 27001493
PQID 1786581504
PQPubID 47786
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5003106
proquest_miscellaneous_1785741237
proquest_journals_1786581504
pubmed_primary_27001493
crossref_primary_10_1373_clinchem_2015_252163
crossref_citationtrail_10_1373_clinchem_2015_252163
PublicationCentury 2000
PublicationDate 2016-05-01
PublicationDateYYYYMMDD 2016-05-01
PublicationDate_xml – month: 05
  year: 2016
  text: 2016-05-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Washington
PublicationTitle Clinical chemistry (Baltimore, Md.)
PublicationTitleAlternate Clin Chem
PublicationYear 2016
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Skates (2020022605332113500_B16) 2013; 12
Pepe (2020022605332113500_B2) 2008; 100
Pauker (2020022605332113500_B7) 1975; 293
U.S. Preventive Services Task Force (2020022605332113500_B10) 2009; 151
Fitzgerald (2020022605332113500_B17) 2015; 313
Menon (2020022605332113500_B14) 2009; 10
2020022605332113500_B15
Pepe (2020022605332113500_B3) 2015; 24
2020022605332113500_B11
Feng (2020022605332113500_B1) 2013; 59
2020022605332113500_B8
Vickers (2020022605332113500_B20) 2014; 60
Pepe (2020022605332113500_B19) 2014; 107
Pepe (2020022605332113500_B6) 2003
Pepe (2020022605332113500_B18) 2008; 100
Vickers (2020022605332113500_B5) 2006; 26
Moertel (2020022605332113500_B9) 1995; 122
Pepe (2020022605332113500_B4) 2001; 93
Bennett (2020022605332113500_B12) 2011; 104
Bucchi (2020022605332113500_B13) 2008; 15
References_xml – year: 2003
  ident: 2020022605332113500_B6
  article-title: The statistical evaluation of medical tests for classification and prediction
  doi: 10.1093/oso/9780198509844.001.0001
– ident: 2020022605332113500_B11
– ident: 2020022605332113500_B8
– ident: 2020022605332113500_B15
– volume: 100
  start-page: 1432
  year: 2008
  ident: 2020022605332113500_B2
  article-title: Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djn326
– volume: 104
  start-page: 571
  year: 2011
  ident: 2020022605332113500_B12
  article-title: Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.3
– volume: 59
  start-page: 68
  year: 2013
  ident: 2020022605332113500_B1
  article-title: Early detection research network specimen reference sets: paving the way for rapid evaluation of potential biomarkers
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2012.185140
– volume: 313
  start-page: 409
  year: 2015
  ident: 2020022605332113500_B17
  article-title: Decision curve analysis
  publication-title: JAMA
  doi: 10.1001/jama.2015.37
– volume: 293
  start-page: 229
  year: 1975
  ident: 2020022605332113500_B7
  article-title: Therapeutic decision making: a cost-benefit analysis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM197507312930505
– volume: 10
  start-page: 327
  year: 2009
  ident: 2020022605332113500_B14
  article-title: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70026-9
– volume: 100
  start-page: 978
  year: 2008
  ident: 2020022605332113500_B18
  article-title: Gauging the performance of SNPs, biomarkers and clinical factors for predicting risk of breast cancer
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djn215
– volume: 107
  start-page: 355
  year: 2014
  ident: 2020022605332113500_B19
  article-title: Net risk reclassification p-values: valid or misleading?
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dju355
– volume: 12
  start-page: 5383
  year: 2013
  ident: 2020022605332113500_B16
  article-title: Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies
  publication-title: J Proteome Res
  doi: 10.1021/pr400132j
– volume: 24
  start-page: 944
  year: 2015
  ident: 2020022605332113500_B3
  article-title: Improving the quality of biomarker discovery research: the right samples and enough of them
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-14-1227
– volume: 93
  start-page: 1054
  year: 2001
  ident: 2020022605332113500_B4
  article-title: Phases of biomarker development for early detection of cancer
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/93.14.1054
– volume: 122
  start-page: 321
  year: 1995
  ident: 2020022605332113500_B9
  article-title: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-122-5-199503010-00001
– volume: 26
  start-page: 565
  year: 2006
  ident: 2020022605332113500_B5
  article-title: Decision curve analysis: a novel method for evaluating prediction models
  publication-title: Med Decis Making
  doi: 10.1177/0272989X06295361
– volume: 15
  start-page: 30
  year: 2008
  ident: 2020022605332113500_B13
  article-title: Incidence of interval breast cancers after 650,000 negative mammographies in 13 Italian health districts
  publication-title: J Med Screen
  doi: 10.1258/jms.2008.007016
– volume: 151
  start-page: 715
  year: 2009
  ident: 2020022605332113500_B10
  article-title: Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
  publication-title: Ann Intern Med
– volume: 60
  start-page: 136
  year: 2014
  ident: 2020022605332113500_B20
  article-title: Does the net reclassification improvement help us evaluate models and markers?
  publication-title: Ann Intern Med
  doi: 10.7326/M13-2841
SSID ssj0004786
Score 2.4630122
Snippet Many cancer biomarker research studies seek to develop markers that can accurately detect or predict future onset of disease. To design and evaluate these...
BACKGROUNDMany cancer biomarker research studies seek to develop markers that can accurately detect or predict future onset of disease. To design and evaluate...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 737
SubjectTerms Aged
Biomarkers
Biomarkers, Tumor - analysis
Breast Neoplasms - diagnosis
Clinical outcomes
Colonic Neoplasms - diagnosis
Costs
Decision theory
Design
Female
Funding
Humans
Middle Aged
Ovarian cancer
Ovarian Neoplasms - diagnosis
Sensitivity and Specificity
Title Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?
URI https://www.ncbi.nlm.nih.gov/pubmed/27001493
https://www.proquest.com/docview/1786581504
https://www.proquest.com/docview/1785741237
https://pubmed.ncbi.nlm.nih.gov/PMC5003106
Volume 62
WOSCitedRecordID wos000375173400016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Earth, Atmospheric & Aquatic Science Database
  customDbUrl:
  eissn: 1530-8561
  dateEnd: 20220430
  omitProxy: false
  ssIdentifier: ssj0004786
  issn: 0009-9147
  databaseCode: PCBAR
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/eaasdb
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1530-8561
  dateEnd: 20220430
  omitProxy: false
  ssIdentifier: ssj0004786
  issn: 0009-9147
  databaseCode: 7X7
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Materials Science Database
  customDbUrl:
  eissn: 1530-8561
  dateEnd: 20220430
  omitProxy: false
  ssIdentifier: ssj0004786
  issn: 0009-9147
  databaseCode: KB.
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/materialsscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Nursing & Allied Health Database
  customDbUrl:
  eissn: 1530-8561
  dateEnd: 20220430
  omitProxy: false
  ssIdentifier: ssj0004786
  issn: 0009-9147
  databaseCode: 7RV
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/nahs
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1530-8561
  dateEnd: 20220430
  omitProxy: false
  ssIdentifier: ssj0004786
  issn: 0009-9147
  databaseCode: BENPR
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 1530-8561
  dateEnd: 20220430
  omitProxy: false
  ssIdentifier: ssj0004786
  issn: 0009-9147
  databaseCode: 8C1
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database
  customDbUrl:
  eissn: 1530-8561
  dateEnd: 20220430
  omitProxy: false
  ssIdentifier: ssj0004786
  issn: 0009-9147
  databaseCode: M2P
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYhxAvfH8UxmQkXrMlsRPbvEx02oQEraqxVX2LbMfWKpWktB0S_z13jttRkOCBl5OiXBIn58udfXe_I-SdAQWrrTYJyxUsUKzyiSmBKM4tL5x0aahKm3wWo5GcTtU4britYlrl5p8YftR1a3GP_DgTEowluC_8ZPEtwa5RGF2NLTT2yD4ilfEe2R-cjcYXt5WRIvR6RE8C1JqLWDzHBDvGykP4LliNnhVHOZixku0apz88zt8TJ3-xROcP__cdHpEH0QelH7pJ85jccc0Tcm8Yo-xPySKgHifja7BwNCYa0tbTwaz9itk8y9V7ipDf9DKkkdMvmATfdaGguqlp6GmPyBRwPNFzGCAd4h4A7coLacQindOrNWbm_jh5Rq7Ozy5PPyaxM0NiizRfJ4yZUmshCm-sl6rQgjmpbZ5nzptaayNTqZyvWeY916ZkwFbrVBoDUyZ3JXtOek3buJeEOq-8tYp7XwruhFOuRoR8kWYGVnKO9wnbiKSyEbYcu2fMqxCLE6zaCLJCQVadIPsk2V616GA7_sF_sJFYFZV4Vd2Kq0_ebk-D-mFMRTeuvQk8BThlORN98qKbHNsHhpg-V3BzsTNttgwI7b17ppldB4jvIkC2lq_-PqzX5D68Q9nlXx6Q3np5496Qu_b7erZaHpI9cTFBOhWBSqDyNDuMOgJHnwZHQIf5-CdTxRyy
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aA8FeuMMKA4wEj2FJ7MQxEpq4TZvWVhPrqr0F27G1Sl3Std2m_Sl-I8dO0lGQ4GkPvESK4lycfD7nOP7OdwDeKBxghZYqoLHACYoWNlApbgRjmiUmM6HPSht2eb-fHR2J_RX40ebCOFplaxO9oS4q7f6Rb0Y8Q2eJ4QvbmpwGrmqUW11tS2jUsNgzlxc4ZZt92P2C3_dtHG9_HXzeCZqqAoFOwngeUKpSKTlPrNI2E4nk1GRSx3FkrCqkVFmYCWMLGlnLpEopNitkmCmF3Y1NSvG6N-Am2vHIUcj4t-FVHib3lSVd3IJGhPEmVY9yuunyHPEruNz3KHkXo9NM6bIr_CO-_Z2m-Yvf2773v72x-3C3ibDJx3pIPIAVUz6E272GQ_AIJl7TOdg_Rv9NGholqSz5NKpOHFdpOntPnKA5GXiSPDlwFP-6xgaRZUEOJsbzGN3-UI7xhZCe-8NB6uRJ0iitjsnh3PGOL7cew-G19PcJrJZVadaBGCus1oJZm3JmuBGmcPr_PIwUzlMN6wBtIZDrRpTd1QYZ536lkdO8BU7ugJPXwOlAsDhrUouS_KP9RouQvDFRs_wKHh14vTiMxsWtGMnSVGe-TYIhZ0x5B57WYFzc0DMWmMCL8yWYLho44fLlI-Xo2AuYJ16QNn3298d6BXd2Br1u3t3t7z2HNexPWjNNN2B1Pj0zL-CWPp-PZtOXfhQS-H7dIP4Jrpt5SQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgiouvB8LBYwEx7CJ7cQxEqqgZUXVdrVSH-ot2I6trrQky-4W1L_Gr2PsJFsWJDj1wCVSFMeJ7c8zY_ubGYBXGidYaZSOGJW4QDHSRTrDi-Tc8NTmNg5eaSf7YjjMT0_laA1-dL4wnlbZycQgqMva-D3yfiJyVJZovvC-a2kRo53B1vRr5DNI-ZPWLp1GA5E9e_Edl2_zd7s7ONavKR18PNr-FLUZBiKTxnQRMaYzpYRInTYul6kSzObKUJpYp0uldB7n0rqSJc5xpTOGxUoV51pj06nNGNZ7Da4Lhij2Xurbl_QSLkKWSW_DoEDhonXbY4L1vc8jjoj3g0_SNxQVaMZW1eIftu7vlM1fdODg9v_ce3fgVmt5k_fNVLkLa7a6BxsHLbfgPkxDrOdodIZ6nbT0SlI78mFcf_Ecptn8LfGBzslRIM-TQ0_9b3JvEFWV5HBqA7_R35-oCXYOOfA7H6RxqiRtBNYJOV54PvLF1gM4vpL2PoT1qq7sYyDWSWeM5M5lglthpS19XgARJxrXr5b3gHVwKEwbrN3nDJkU4QRSsKIDUeFBVDQg6kG0fGvaBCv5R_nNDi1FK7rmxSVUevBy-RiFjj9JUpWtz0OZFE1RykQPHjXAXH4wMBm4xMrFCmSXBXxA89Un1fgsBDZPQ6Da7Mnff-sFbCB2i_3d4d5TuInNyRoC6iasL2bn9hncMN8W4_nseZiQBD5fNYZ_AsI6gaQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+Phase+Studies+of+Biomarkers%3A+What+Target+Sensitivity+and+Specificity+Values+Might+Confer+Clinical+Utility%3F&rft.jtitle=Clinical+chemistry+%28Baltimore%2C+Md.%29&rft.au=Pepe%2C+Margaret+S.&rft.au=Janes%2C+Holly&rft.au=Li%2C+Christopher+I.&rft.au=Bossuyt%2C+Patrick+M.&rft.date=2016-05-01&rft.issn=0009-9147&rft.eissn=1530-8561&rft.volume=62&rft.issue=5&rft.spage=737&rft.epage=742&rft_id=info:doi/10.1373%2Fclinchem.2015.252163&rft_id=info%3Apmid%2F27001493&rft.externalDocID=PMC5003106
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9147&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9147&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9147&client=summon